GP (HK)’s Independently Developed Innovative Glaucoma Treatment Drug Obtained Drug Registration Certificate Breaking Through the Blue Ocean of The Ophthalmic Market Segment and Consolidating its Leading Position in Ophthalmic Drugs 2021-3-4 Corporate News READ MORE
GP (HK)’s First-In-Class Drug STC3141 for Sepsis has been Granted A “Notice of Approval for Clinical Trial of Drugs” Issued by the NMPA and Approved to Carry out Phase Ib Clinical Trial on ARDS Highlights its Ability to Implement the Commercialization of R&D Results 2021-3-4 Corporate News READ MORE
GP (HK) Announces Positive Profit Alert The Expected Increase in Consolidated Net Profit Attributable to Owners of the Company for FY2020 No Less Than 40% 2021-2-21 Corporate News READ MORE
First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141 Promote Commercialization of Technological Innovation Pipelines Globally at Full Speed First-mover Advantages in Anti-virus and Anti-infection Area Come into Play 2020-12-13 Corporate News READ MORE
GP (HK)’s Associate Sirtex Enters into Transactions and Strategic Cooperation with Nanospectra and BlackSwan Expands the Group’s Product Portfolio in Precision Interventional Diagnostics and Treatment and Continues to Propel Global Planning of Technological Innovation 2020-12-9 Corporate News READ MORE
GP(HK) and eTheRNA Enters into Exclusive Strategic Cooperation and Licensing Agreement on World-class Innovative Products in Greater China Region Promotes Technology Transfer of mRNA Vaccine Platform to Strengthen International Strategic Planning Covering Multiple Therapeutic Fields with High Innovative Entry Barrier 2020-11-29 Corporate News READ MORE
NDA for Y-90 Resin Microspheres of GP(HK) Accepted by NMPA and NDA for Prostate Cancer Imaging RDC Product TLX591-CDx Accepted by FDA, Actively Promote the Commercialization Process of Innovative Products and Expand Strategic Planning in the Field of Radiopharmaceuticals 2020-11-25 Corporate News READ MORE
GP(HK) Enters into A Few Agreements in the Field of Cancer Diagnostics and Treatment Introduce Multiple RDC and Strengthen Strategic Planning and Innovation in Anti-tumor Field 2020-11-1 Corporate News READ MORE
Four Products of GP (HK) that Obtained Consistency Evaluation Approvals, Namely Sodium Bicarbonate Tablets, Trimetazidine Tablets, Finasteride Tablets and Captopril Tablets, Have Successfully Won the Bids in the Third Batch of National Centralized Drug Procurement 2020-8-20 Corporate News READ MORE
GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily 2020-8-10 Corporate News READ MORE
GP (HK) Enters into a Capital Subscription and Acquisition Agreement, Acquires the Third-Generation Stent Retriever Contributing to Achieve the Strategic Plan of “Treating the Heart and Brain with the Same Therapeutic Method”, Enhancing Global “Precision Diagnostics + Treatment” Planning 2020-7-28 Corporate News READ MORE
GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy 2020-7-15 Corporate News READ MORE
English
